glutathione heart disease and Cardiovascular Health Frontiers | Progress in the

59, 143166.10.1146/annurev.arplant.59.032607.092811 55 RegseggerA.SchmutzD.BrunoldC

One such trial, from 2020, had inconclusive results on SS-31s benefits for heart failure, but it described the peptide as well tolerated and reported no significant increases in blood pressure, heart rate, or electrocardiogram intervals.29 Another trial, from the same year, yielded no significant benefit for mitochondrial myopathy but found the only noteworthy adverse effects to be injection site reactions, the majority of which were mild.35 These findings are consistent with the risks described by the clinicians we know who prescribe SS-31, though they add that some users may also experience headaches , dizziness , gastrointestinal distress , flushing , or fatigue

The original clinical development, by the Canadian biotech ConjuChem, was discontinued, and there is no validated disease endpoint for either version

doi: 10.3945/ajcn.2010.29732